Aska Report

Overview

The report marks ASKA Pharmaceutical's 100th anniversary and describes the company's continued focus on internal medicine, Ob/Gyn and urology. FY2019 consolidated net sales reached a record ¥52,542 million, although the ¥70 billion ASKA PLAN 2020 target was not achieved. The company highlights the 2020 launch of Mint+ Health Lab for Women and prioritizes six SDGs, including Goals 3, 5, 7, 12, 13 and 17. It also outlines the planned FY2021 transition to a holding company structure intended to strengthen group governance.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2019
Period: 1 April 2019 – 31 March 2020
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services